Related Experiment Videos
Insulin-like growth factor-binding protein 1 and insulin-like growth factor-binding protein 3 in pre-eclampsia
1Department of Obstetrics and Gynaecology, Chang-Gung Memorial Hospital, Lin-Kou Medical Centre, Taipei, Taiwan, R.O.C.
Insights
Maternal and fetal insulin-like growth factor-binding protein 1 (IGFBP-1) and IGFBP-3 levels were altered in pre-eclampsia with intrauterine growth retardation (IUGR). These changes may reflect low birthweight in pre-eclampsia.
Area of Science:
- Reproductive Endocrinology
- Maternal-Fetal Medicine
- Biochemistry
Background:
- Pre-eclampsia is a serious pregnancy complication.
- Insulin-like growth factor-binding proteins (IGFBPs) play crucial roles in fetal growth.
- Altered IGFBP levels may be associated with pre-eclampsia and intrauterine growth retardation (IUGR).
Purpose of the Study:
- To investigate circulating levels of insulin-like growth factor-binding protein 1 (IGFBP-1) and IGFBP-3 in mothers and fetuses with pre-eclampsia.
- To examine the relationship between serum IGFBP levels and fetal birthweight in pre-eclamptic pregnancies.
Main Methods:
- Prospective study conducted over 18 months at a tertiary care academic medical center.
- Included 66 pregnant women with pre-eclampsia and 78 non-pre-eclamptic controls.
- Measured serum concentrations of IGFBP-1 and IGFBP-3 at delivery.
Main Results:
- In pre-eclampsia with IUGR, maternal and cord serum IGFBP-1 levels were elevated.
- Circulating IGFBP-3 levels were lower in mothers and fetuses with pre-eclampsia and IUGR compared to controls.
- No significant differences in IGFBP-1 and IGFBP-3 levels were found in pre-eclampsia without IUGR.
Conclusions:
- Elevated IGFBP-1 and decreased IGFBP-3 were observed in mothers and fetuses with pre-eclampsia.
- These biochemical changes may be indicative of, or secondary to, low birthweight associated with pre-eclampsia.
Objective:
To investigate circulating levels of insulin-like growth factor-binding protein 1 (IGFBP-1) and IGFBP-3 in the mother and the fetus in pregnancies complicated by pre-eclampsia, and the relationship between serum levels of IGFBPs and fetal birthweight.
Design:
A prospective study over an 18 month period.
Setting:
A tertiary care academic medical centre.
Participants:
Sixty-six pregnant women with pre-eclampsia (35 cases of mild/moderate pre-eclampsia and 31 cases of severe pre-eclampsia) and 78 nonpre-eclamptic pregnant women of matched gestational weeks and maternal ages.
Main Outcome Measures:
Serum concentrations of IGFBP-1 and IGFBP-3 at the time of delivery.
Results:
In pre-eclampsia associated with intrauterine growth retardation (IUGR), maternal and cord serum IGFBP-1 levels at the time of delivery were elevated. By contrast, circulating IGFBP-3 levels in both the mother and the fetus were lower in pre-eclampsia with IUGR than in nonpre-eclamptic pregnancy. However, there was no difference in serum IGFBP-1 and IGFBP-3 levels between pre-eclampsia without IUGR and nonpre-eclamptic pregnancy in both the mother and the fetus.
Conclusions:
In pre-eclampsia, elevated concentrations of circulating IGFBP-1 and decreased serum IGFBP-3 levels were observed in both the mother and the fetus. However, these changes may simply reflect low birthweight in pre-eclampsia.